Overview

Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Status:
Completed

Trial end date:
2021-01-13

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in healthy Chinese male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Shandong Boan Biotechnology Co., Ltd

Treatments:

Bevacizumab
Endothelial Growth Factors